pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry

BACKGROUND: AZD0156 and AZD6738 are potent and selective inhibitors of ataxia-telangiectasia-kinase (ATM) and ataxia-telangiectasia-mutated and Rad3-related (ATR), respectively, important sensors/signallers of DNA damage. METHODS: We used multiplexed targeted-mass-spectrometry to select pRAD50(Ser63...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Gemma N., Rooney, Claire, Griffin, Nicola, Roudier, Martine, Young, Lucy A., Garcia-Trinidad, Antonio, Hughes, Gareth D., Whiteaker, Jeffrey R., Wilson, Zena, Odedra, Rajesh, Zhao, Lei, Ivey, Richard G., Howat, William J., Harrington, Elizabeth A., Barrett, J. Carl, Ramos-Montoya, Antonio, Lau, Alan, Paulovich, Amanda G., Cadogan, Elaine B., Pierce, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251026/
https://www.ncbi.nlm.nih.gov/pubmed/30385821
http://dx.doi.org/10.1038/s41416-018-0286-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251026/
https://www.ncbi.nlm.nih.gov/pubmed/30385821
http://dx.doi.org/10.1038/s41416-018-0286-4

Ejemplares similares